Previous Article | Next Article ![]()
Journal of Clinical Microbiology, January 2004, p. 449-452, Vol. 42, No. 1
0095-1137/04/$08.00+0 DOI: 10.1128/JCM.42.1.449-452.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo,1 Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina, UNIFESP, São Paulo,10 Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiania, Brazil,2 Instituto de Investigaciones en Engenieria Genética y Biologia Molecular (INGEBI), Buenos Aires, Argentina,3 Laboratorio de Referencia para Enfermedad de Chagas y Leishmaniasis, Secretaria de la Salud, Tegucigalpa, Honduras,4 Departamento de Ciencias Biologicas, Universidad Simon Bolivar, Caracas, Venezuela,5 Instituto de Servicios de Laboratório de Diagnóstico e Investigacion en Salud (Seladis), La Paz, Bolívia,6 Departamento de Inmunologia, Instituto de Investigaciones Biomédicas, Universidad Autonoma de Mexico, Mexico DF, México,7 Centro de Investigacion y Diagnóstico de Enfermedades Parasitárias, Facultad de Medicina, Universidad de Panama, Panama, Panama,8 Division of Human Health, International Atomic Energy Agency, Vienna, Austria9
Received 17 June 2003/ Returned for modification 21 July 2003/ Accepted 23 September 2003
An enzyme-linked immunosorbent assay to diagnose Chagas' disease by a serological test was performed with Trypanosoma cruzi recombinant antigens (JL8, MAP, and TcPo). High sensitivity (99.4%) and specificity (99.3%) were obtained when JL8 was combined with MAP (JM) and tested with 150 serum samples from chagasic and 142 nonchagasic individuals. Moreover, JM also diagnosed 84.2% of patients in the acute phase of T. cruzi infection.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»